Meeting Banner
Abstract #1726

Selective Acidification and De-Energization of LNCaP Prostate Cancer Xenografts Using Lonidamine

Kavindra Nath1, Ting Liu1, David S. Nelson1, Hoon Choi2, I-Wei Chen2, Dennis B. Leeper3, Rong Zhou1, Jerry D. Glickson1

1Radiology, University of Pennsylvania, Philadelphia, PA, United States; 2Materials Science and Engineering, University of Pennsylvania, philadelphia, PA, United States; 3Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, United States

Synopsis: In vivo 31P Magnetic Resonance Spectroscopy demonstrates that LNCaP prostate cancer xenografts treated with the putative monocarboxylate transporter (MCT) inhibitor, lonidamine (LND), exhibits a sustained and tumor-selective decrease in intracellular pH (pHi) from 6.87 0.04 to 6.40 0.07 (p = 0.02), extracellular pH (pHe) from 6.97 0.04 to 6.46 0.09 (p = 0.18) and tumor bioenergetics (βNTP/Pi) also decreased by 74.5 0.04% (p = 0.03) relative to the baseline level following LND administration. The decline of pHi, pHe and bioenergetics could be a critical parameter for thermosensitization and/or improving tumor response to alkylating agents.